2026 AAFP FMX - From Evidence to Exam Room: GLP-1 RA Therapy in Primary Care

HAZLET, N.J. - EntSun -- Three experts in the management of T2D and cardiovascular risk will guide attendees through the evidence, guidelines, and exam room conversations and prescribing decisions that will improve the outcomes for their patients.

Click here for more information

CHAIR
Jay Shubrook, DO, FACOFP, FAAFP
Professor & Diabetologist
Department of Clinical Sciences &
Community Health
Diabetes Institute
Touro University California College of
Osteopathic Medicine
Vallejo, California

FACULTY
Silvio Inzucchi, MD
Clinical Chief of the Section of Endocrinology
Professor of Medicine
Yale University School of Medicine
New Haven, Connecticut

Lawrence A. Leiter, MD, FRCPC
Division of Endocrinology & Metabolism
St. Michael's Hospital
Professor of Medicine & Nutritional Sciences
University of Toronto
Toronto, Canada

More on EntSun News

• May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
• Anti-Bullying Film The Karate Weirdo Secures Global Streaming Acquisition
• Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
• MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
• Metamora Events Brings New Interactive Event Experiences to Portland and Vancouver

Educational Objectives
■ Apply the 2026 ADA Standards of Care guideline recommendations to
identify primary care patients with T2D who are candidates for GLP-1
RA therapy, including those with established ASCVD, CKD, or multiple
cardiovascular risk factors
■ Interpret the cardiovascular outcomes trial evidence with GLP-1 RA therapy
and translate key findings into clinical decisions for primary care patients
with T2D
■ Initiate oral or injectable GLP-1 RA therapy in appropriate primary care
patients with T2D, including patients who are injection-averse, using
correct dosing, titration, and administration guidance
■ Counsel primary care patients with T2D on the benefits, tolerability,
administration requirements, and class safety profile of GLP-1 RA therapy
to support shared decision-making and long-term adherence

Target Audience
This program is intended for primary care clinicians and other healthcare
professionals who manage patients with T2D and ASCVD risk.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant from

More on EntSun News

• Disruptor Creations Options Untitled Feature Film Written by David Krumholtz and Johnny Markows
• The ABC's of Insurance Celebrates 600th TV Episode
• Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
• Revamping Fashion Sourcing: Speed and Flexibility Explained by Fashion Sourcing
• How Fashion Sourcing Has Become A Leader At Sourcing Las Vegas

Novo Nordisk Inc.

Accreditation and Credit Designation Statements
This live activity, From Evidence to Exam Room: GLP-1 RA Therapy in Primary Care, with a beginning date of 10/23/26, has been reviewed and is acceptable for up to 1.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.